Annual Report

Overview

The report describes Renalytix's FY24 progress from development to commercial execution, including FDA De Novo authorization, expanded insurance coverage and continued Medicare payments for kidneyintelX.dkd. The company reported $2.3 million in group revenue for the year ended 30 June 2024 and a $45.5 million loss. It also reports more than $11 million in annual operating expense reductions versus the prior year.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2024
Period: Ends 30 June 2024
Publication date: 20 November 2024
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services